An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer.

Cancer Res Treat · 2017 · PMC5512366 · PMID 27618821

Europe PMC DOI

hedged sentence

0.5200

closest p · 10.4× alpha

0.5200

boldest claim

The sentences

did not reach statistical significancep=0.52not close (p > 0.1)

The between-group difference in OS did not reach statistical significance (p=0.52) ( Fig. 3A ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.